Geron (GERN) taps Inspiration Biopharmaceuticals' Andrew Grethlein to oversee its manufacturing...


Geron (GERN) taps Inspiration Biopharmaceuticals' Andrew Grethlein to oversee its manufacturing and quality functions as EVP of technical operations. Geron's fresh off disappointing investors by stopping a trial of its imetelstat as a breast cancer treatment and dropped 51.4% last week.
Comments (12)
  • pvhayes
    , contributor
    Comments (5) | Send Message
     
    long time admirer of GERN's potential...more recently just long...hanging in for now...
    17 Sep 2012, 01:23 PM Reply Like
  • ElFuego1
    , contributor
    Comment (1) | Send Message
     
    I bought at 2.80.(ouch)..and also am holding on. Is this stock coming back up?
    17 Sep 2012, 01:33 PM Reply Like
  • jbl898
    , contributor
    Comments (8) | Send Message
     
    It is already bouncing back and they have other great stuff in their pipeline. Hamg in there.
    18 Sep 2012, 09:48 AM Reply Like
  • pvhayes
    , contributor
    Comments (5) | Send Message
     
    looks like they are down to one remaining cancer clinical trial ....drug is called GERN something. wish I knew. I will likely ride it to the bottom, if necessary. Hate to see early investors pay for the science and then a larger company scoop up the IP for a song later.....
    18 Sep 2012, 09:51 AM Reply Like
  • Robert Lawton
    , contributor
    Comments (253) | Send Message
     
    Not correct.
    They still have 4 ongoing phase II's which are viable. Promising even.
    2 in "liquid tumors" ; results expected between 10/1/12-12/31/12
    2 for GRN 1005, designed to cross BBB, results expected 2013 Q2.
    Interim results on 12/7/12
    Really surprises me that you're "long" but don't know this.
    Why did you buy it?
    18 Sep 2012, 06:26 PM Reply Like
  • pvhayes
    , contributor
    Comments (5) | Send Message
     
    good question....not my field, but sounded good...liked the potential for a long time, but worried now because of the shift away from stem cell research and most recently the discontinuation of what I took to be one of two remaining avenues to profitability in the cancer area. Thanks for the reassurance....hope this doesn't turn out to be another example of science at the expense of the retail investor....beginning to remind me of Venter's Celera Genomics....hope not.
    19 Sep 2012, 12:56 PM Reply Like
  • Robert Lawton
    , contributor
    Comments (253) | Send Message
     
    Understood.
    All best,
    RL
    19 Sep 2012, 06:24 PM Reply Like
  • Scrying Biotech
    , contributor
    Comments (2740) | Send Message
     
    I remember back at the time of the Helix Investment article and the ensuing run up the ladder how excited everyone was including me. I couldn't jump on board as my money was tied up elsewhere but would have. The imetelstat announcement was such a blindside. It taught all of us a lesson about not relying on the calendar too much - that news happens when it wants and usually surprises one way or the other. I feel for you guys. I got Zynga at 3.08. It's looking like a bust too. We'll see. Hang in there and good luck!
    10 Oct 2012, 04:23 AM Reply Like
  • pvhayes
    , contributor
    Comments (5) | Send Message
     
    ...just took a look at GERN...down to $1.38 a share this am....I'll sell you some :-)
    Speaking of news......I am recently a bit concerned about the news related to the huge chunk of dna that was until recently deemed to be not used, useless....and now they think it is a bunch of switches to selectively turn on/off the rest of the "useful" genes....this looks like it has the possibility to trump GERN's IP? ....take this thought with a grain of salt, as I say this is not my field...apologies for the layman terminology.
    10 Oct 2012, 10:17 AM Reply Like
  • Scrying Biotech
    , contributor
    Comments (2740) | Send Message
     
    Interesting. I know your comment has something to do with actual science. Mine is just stream of consciousness drivel but I have always believed this to be true - that as our environment, needs, and capabilities change our genetics change with them. There must be a gene somewhere for the ability to sit in front of a television for hours on end and play video games. I don't have that one "on" but my sons do.
    10 Oct 2012, 12:59 PM Reply Like
  • pvhayes
    , contributor
    Comments (5) | Send Message
     
    Nintendo can fix you up Michael....pick up one of those new 3ds xl's....my sons have this gene activated as well....I still prefer chess....try explaining the enjoyment of chess to a ds addict.....alas we digress.
    Is GERN going to turn the corner and make a buck for long retail investors? .....or at least be bought out by big pharma?
    or will they go the way of Celera Genomics.....down the tubes after doing great science.
    11 Oct 2012, 08:57 AM Reply Like
  • Scrying Biotech
    , contributor
    Comments (2740) | Send Message
     
    I'll check it out! And I hope I'm reading about a successful Phase II trial that leads to great things for Geron. They deserve it! And so do their investors...
    11 Oct 2012, 12:49 PM Reply Like
DJIA (DIA) S&P 500 (SPY)
ETF Hub
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs